Adam S. Grossman - Oct 25, 2021 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Signature
/s/ Adam S. Grossman, by Brian Lenz as Attorney-in-fact
Stock symbol
ADMA
Transactions as of
Oct 25, 2021
Transactions value $
$350,000
Form type
4
Date filed
10/26/2021, 07:00 AM
Previous filing
Oct 1, 2021
Next filing
Mar 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMA Common Stock Purchase $100K +100K +4.91% $1.00* 2.14M Oct 25, 2021 Direct F1, F2, F3, F4, F5
transaction ADMA Common Stock Purchase $250K +250K +28.46% $1.00* 1.13M Oct 25, 2021 See Footnote F1, F6
holding ADMA Common Stock 581K Oct 25, 2021 See Footnote F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a purchase from the underwriters in the October 2021 public offering of the issuer.
F2 Includes (i) 907,500 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;
F3 (ii) 742,500 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;
F4 (iii) 221,447 RSUs granted on February 25, 2021, of which 183,150 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 38,297 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;
F5 (iv) 75,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 191,169 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F6 These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
F7 These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.